RECRUITING

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI. The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).

Official Title

Utility of Hyperpolarized 13C-Pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis of Early Cerebral Metabolic Crisis After Traumatic Brain Injury

Quick Facts

Study Start:2023-10-26
Study Completion:2026-11-26
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06103201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * History of acute head injury with or suspected non-penetrating acute TBI
  2. * Suitable to undergo contrast-enhanced MRI
  3. * Negative serum pregnancy test
  1. * Inability to undergo MRI scan
  2. * Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency
  3. * Positive pregnancy test

Contacts and Locations

Study Contact

Rosy Linda Njonkou Tchoquessi
CONTACT
410-706-0943
rnjonkou@som.umaryland.edu

Principal Investigator

Dirk Mayer, Dr. rer. nat.
PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore

Study Locations (Sites)

University of Maryland Baltimore
Baltimore, Maryland, 21201
United States

Collaborators and Investigators

Sponsor: University of Maryland, Baltimore

  • Dirk Mayer, Dr. rer. nat., PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-26
Study Completion Date2026-11-26

Study Record Updates

Study Start Date2023-10-26
Study Completion Date2026-11-26

Terms related to this study

Additional Relevant MeSH Terms

  • Traumatic Brain Injury
  • Subarachnoid Hemorrhage